Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
BMS Recruiting Study icon

Recruiting

Trial ID CC-220-MM-002  |   NCT04975997

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Summary

  • Phase 3
  • Male and Female Gender icon
  • 18+
    Age Range
  • 122
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Documented diagnosis of multiple myeloma (MM) and measurable disease.
    1. Received 1 to 2 prior lines of anti-myeloma therapy.
      1. Must have documented disease progression during or after their last anti-myeloma regimen.
        1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.

          Exclusion Criteria

          Exclusion Criteria Icon
          • Any condition that confounds the ability to interpret data from the study.
            1. Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.
              1. Known central nervous system involvement with MM.
                1. Prior therapy with iberdomide.
                  Additional Information *
                  • Other protocol-defined Inclusion/Exclusion criteria apply.

                    Treatment Options

                    Study Arms

                    ASSIGNED INTERVENTION

                    Study Arms

                    Active Comparator: Daratumumab in combination with dexamethasone and bortezomib

                    ASSIGNED INTERVENTION
                    • Drug: Dexamethasone, Daratumumab, Bortezomib

                    Study Arms

                    Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 1

                    ASSIGNED INTERVENTION
                    • Drug: Dexamethasone, Daratumumab, Iberdomide

                    Study Arms

                    Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 2

                    ASSIGNED INTERVENTION
                    • Drug: Dexamethasone, Daratumumab, Iberdomide

                    Study Arms

                    Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 3

                    ASSIGNED INTERVENTION
                    • Drug: Dexamethasone, Daratumumab, Iberdomide
                    Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                    Check Your Eligibility
                    Answer some questions about Your health to see if you may match to this trial
                    Match to a Trial
                    If you are a match, click on the study to see the list of study site locations
                    Select a Study Site Location
                    Select a study site location that is convenient for you
                    Register
                    Provide your contact details for the study site to connect with you.

                    Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you